منشور في 2007
"…In this work, we exploited the extracellular binding property of trastuzumab,
a clinically therapeutic monoclonal antibody to the second member of the HER family (HER2), to design
a diagnostic imaging agent, (111In-DTPA)n-trastuzumab-(IRDye 800CW)m, that is dual labeled with 111In,
a γ-emitter, and
a near-infrared (NIR) fluorescent dye, IRDye 800CW, to detect HER2 overexpression in breast cancer cells. …"
احصل على النص الكامل
احصل على النص الكامل
احصل على النص الكامل
احصل على النص الكامل
article